Go to main content
Lithuania
1
MODESTAS JOCIUS, PHD. PHARM REGIONAL MANAGER BALTICS

“It is a privilege to apply my pharmaceutical and business education and more than 25 years of professional experience to improve the lives of people with rare diseases in Lithuania. We have been operating here since 2009 and will continue to provide innovative and efficient treatment solutions!"

Facts & Figures

AOP Health is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.

Our motivation at AOP Health is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Lithuanian health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases. 

Lithuania occupies a special position among many countries where AOP Health is represented. In this market, the company began its development in 2009 with a local team  in the Marketing & Sales, and Medical for all three therapeutic divisions.

 

100,000
people
PATIENTS WITH RARE DISEASES IN Lithuania 
In Europe those diseases that occur in less than 5 per 10,000 residents are defined as rare diseases. In Lithuania 100,000 people have been diagnosed with a rare disease.
AVAILABLE TREATMENTS
In Lithuania AOP Health provides six products. 
 
6
products
3
areas
THREE THERAPEUTIC AREAS
AOP Health in Lithuania covers three area of treatments: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders.

Vision & Mission

Milestones

History of more than 20 years means many significant milestones — in research,  social, business spheres and regulatory affairs — that were and are important for AOP Health.

1996

Foundation of AOP Health in Vienna

1999

The Orphan Regulation EC no 141/2000

2001

1st Approval of Anagrelide in Europe

2004

European Union Expansion

2005

Prostacyclin Analogues Approval

2005

JAK2 Discovery

2008

Renaissance of Interferon (IFNα)

2010

UDCA Designation

2010

Tetrabenazine Approval in Central Europe

2012

Nabilone Approval in Austria

2013

Start of the PROUD PV Study

2015

Beta-blocker for severe sepsis

2016

Pitolisant approval

2017

Landiolol approval

2018

Treprostinil and PAH

2019

BESREMi® Approval

SCIENCE & INNOVATION
From the Concept to the Drug  

AOP Health headquarters team in Vienna covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance. Find out more about Science & Innovation at AOP Health in English on the global website. 

more on the global website
CONNECTED WORLDWIDE
Partnering  

Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about cooperation ways with AOP Health using the link below.

more on the global website

Corporate culture

Thanks to many years of experience in the provision of complex and individualized treatments, AOP Health gained special expertise and market presence in the field of rare diseases.

Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders. 

AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.

The future

Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.

Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.

Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.